Genetics of Hypertrophic Cardiomyopathy After 20 Years

Braunwald, 1964, Idiopathic hypertrophic subaortic stenosis, Circulation, 30, 3 Teare, 1958, Asymmetrical hypertrophy of the heart in young adults, Br Heart J, 20, 1, 10.1136/hrt.20.1.1 Maron, 2002, Hypertrophic cardiomyopathy: a systematic review, JAMA, 287, 1308, 10.1001/jama.287.10.1308 Maron, 2003, ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy, J Am Coll Cardiol, 42, 1687, 10.1016/S0735-1097(03)00941-0 Seidman, 2011, Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history, Circ Res, 108, 743, 10.1161/CIRCRESAHA.110.223834 Maron, 2009, Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance, J Am Coll Cardiol, 54, 220, 10.1016/j.jacc.2009.05.006 Maron, 1995, Prevalence of hypertrophic cardiomyopathy in a general population of young adults, Circulation, 92, 785, 10.1161/01.CIR.92.4.785 Jarcho, 1989, Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1, N Engl J Med, 321, 1372, 10.1056/NEJM198911163212005 Geisterfer-Lowrance, 1990, A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation, Cell, 62, 999, 10.1016/0092-8674(90)90274-I Watkins, 1992, Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy, N Engl J Med, 326, 1108, 10.1056/NEJM199204233261703 Ho, 2010, Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy, Circulation, 122, 2430, 10.1161/CIRCULATIONAHA.110.978924 Watkins, 2000, Sudden death in hypertrophic cardiomyopathy, N Engl J Med, 342, 422, 10.1056/NEJM200002103420609 Richard, 2003, Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy, Circulation, 107, 2227, 10.1161/01.CIR.0000066323.15244.54 Henry, 1973, Asymmetric septal hypertrophy, Circulation, 47, 225, 10.1161/01.CIR.47.2.225 Tester, 2011, Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice, Circulation, 123, 1021, 10.1161/CIRCULATIONAHA.109.914838 Niimura, 1998, Mutations in the gene for human cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy, N Engl J Med, 338, 1248, 10.1056/NEJM199804303381802 Ackerman, 2002, Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T gene in hypertrophic cardiomyopathy, J Am Coll Cardiol, 39, 2042, 10.1016/S0735-1097(02)01900-9 Van Driest, 2002, Prevalence and severity of benign mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy, Circulation, 106, 3085, 10.1161/01.CIR.0000042675.59901.14 Erdmann, 2003, Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy, Clin Genet, 64, 339, 10.1034/j.1399-0004.2003.00151.x Andersen, 2009, Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives, Hum Mutat, 30, 363, 10.1002/humu.20862 Landstrom, 2010, Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy, Circulation, 122, 2441, 10.1161/CIRCULATIONAHA.110.954446 Richards, 2008, ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007, Genet Med, 10, 294, 10.1097/GIM.0b013e31816b5cae Mestroni, 2011, Hearing the noise the challenges of human genome variation in genetic testing, J Am Coll Cardiol, 57, 2328, 10.1016/j.jacc.2011.02.026 Meder, 2011, Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies, Circ Cardiovasc Genet, 4, 110, 10.1161/CIRCGENETICS.110.958322 2010, A map of human genome variation from populations—scale sequencing, Nature, 467, 1061, 10.1038/nature09534 Ackerman, 2011, HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies, Heart Rhythm, 8, 1308, 10.1016/j.hrthm.2011.05.020 Maron, 2004, Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy, J Am Coll Cardiol, 44, 2125, 10.1016/j.jacc.2004.08.052 Maron, 2005, 36th Bethesda Conference: eligibility recommendations for competitive athletes with cardiovascular abnormalities, J Am Coll Cardiol, 45, 1312, 10.1016/j.jacc.2005.02.006 Maron, 2011, Clinical challenges of genotype positive (+) – phenotype negative (−) family members in hypertrophic cardiomyopathy, Am J Cardiol, 107, 604, 10.1016/j.amjcard.2010.10.022 Germans, 2006, Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathies mutations, J Am Coll Cardiol, 48, 2518, 10.1016/j.jacc.2006.08.036 Maron, 2011, Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy, Circulation, 124, 40, 10.1161/CIRCULATIONAHA.110.985812 Maron, 2008, Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy, Circulation, 118, 1541, 10.1161/CIRCULATIONAHA.108.781401 Christiaans, 2009, Ventricular fibrillation in MYH7-related hypertrophic cardiomyopathy before onset of ventricular hypertrophy, Heart Rhythm, 6, 1366, 10.1016/j.hrthm.2009.04.029 Semsarian, 2002, The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model, J Clin Invest, 109, 1013, 10.1172/JCI200214677 Patel, 2001, Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy, Circulation, 104, 317, 10.1161/01.CIR.104.3.317 Arad, 2005, Glycogen storage diseases presenting as hypertrophic cardiomyopathy, N Engl J Med, 352, 362, 10.1056/NEJMoa033349 Maron, 2009, Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy, JAMA, 301, 1253, 10.1001/jama.2009.371 Maron, 2010, Profound left ventricular remodeling associated with LAMP2 cardiomyopathy, Am J Cardiol, 106, 1194, 10.1016/j.amjcard.2010.06.035 Weidemann, 2009, Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy, Circulation, 119, 524, 10.1161/CIRCULATIONAHA.108.794529 Patel, 2011, Cardiovascular events in patients with Fabry disease, J Am Coll Cardiol, 57, 1093, 10.1016/j.jacc.2010.11.018 Ciró, 1983, Heterogeneous morphologic expression of genetically transmitted hypertrophic cardiomyopathy: two-dimensional echocardiographic analysis, Circulation, 67, 1227, 10.1161/01.CIR.67.6.1227 Maron, 2010, Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance: implications for management strategies, Am J Cardiol, 105, 1842, 10.1016/j.amjcard.2010.01.367 Maron, 2011, Delayed onset of apical hypertrophic cardiomyopathy in adulthood, Am J Cardiol, 108, 1783, 10.1016/j.amjcard.2011.07.048 Saltzman, 2010, Short communication: the cardiac myosin binding protein C Arg502Trp mutation: a common cause of hypertrophic cardiomyopathy, Circ Res, 106, 1549, 10.1161/CIRCRESAHA.109.216291 Olivotto, 2008, Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy, Mayo Clin Proc, 83, 630, 10.1016/S0025-6196(11)60890-2 Gersh, 2011, 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy, J Am Coll Cardiol, 58, 2703, 10.1016/j.jacc.2011.10.825 Semsarian, 1997, Sudden cardiac death in familial hypertrophic cardiomyopathy: are ”benign” mutations really benign?, Pathology, 29, 305, 10.1080/00313029700169155 Maron, 2007, Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy, JAMA, 298, 405, 10.1001/jama.298.4.405 Ingles, 2005, Compound and double mutations in hypertrophic cardiomyopathy patients: implications for genetic testing and counseling, J Med Genet, 42, e59, 10.1136/jmg.2005.033886 Kelly, 2009, Multiple mutations in genetic cardiovascular disease: a marker of disease severity?, Circ Cardiovasc Genet, 2, 182, 10.1161/CIRCGENETICS.108.836478 Maron, 2012, Double or compound sarcomere mutations associated with sudden death in hypertrophic cardiomyopathy in the absence of conventional risk factors, Heart Rhythm, 9, 57, 10.1016/j.hrthm.2011.08.009 Basille, 2009, Preimplantation genetic diagnosis: state of the art, Eur J Obstet Gynecol Reprod Biol, 145, 9, 10.1016/j.ejogrb.2009.04.004 Ingles, 2011, The emerging role of the cardiac genetic counselor, Heart Rhythm, 8, 1958, 10.1016/j.hrthm.2011.07.017 Abiola, 2008, Recent developments in health law, J Law Med Ethics, 36, 856, 10.1111/j.1748-720X.2008.00344.x Bagnall, 2011, Molecular diagnostics of cardiomyopathies: the future is here, Circ Cardiovasc Genet, 4, 103, 10.1161/CIRCGENETICS.110.959247